Austrian drug maker’s restructuring succumbs to coronavirus pandemic
An Austrian drugs and medical equipment manufacturer, whose restructuring was being overseen by Stefan Riel, will now enter liquidation after investors pulled out of a capital increase citing the coronavirus pandemic’s impact on sales.
To read more
Subscribe to Global Restructuring Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Restructuring Review experts.